{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:47:38Z","timestamp":1792158458609,"version":"4.4.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NO"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-026-03157-0","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:01:59Z","timestamp":1792148519000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the eIF4F translation initiation complex disrupts BCR::ABL1 translation and overcomes drug resistance in CML"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8586-6092","authenticated-orcid":false,"given":"Ryan","family":"Yen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3981-0978","authenticated-orcid":false,"given":"Michael M.","family":"Lizardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3286-7226","authenticated-orcid":false,"given":"Josephine","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna L.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poul H.","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Pelech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8974-7340","authenticated-orcid":false,"given":"Xiaoyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"3157_CR1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldman","year":"2003","unstructured":"Goldman JM, Melo JV. Chronic myeloid leukemia\u2013advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451\u201364.","journal-title":"N Engl J Med"},{"key":"3157_CR2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079\u201382.","journal-title":"Science"},{"key":"3157_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561\u20136.","journal-title":"Nat Med"},{"key":"3157_CR4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"3157_CR5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"3157_CR6","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2009-05-222471","volume":"116","author":"X Jiang","year":"2010","unstructured":"Jiang X, Forrest D, Nicolini F, Turhan A, Guilhot J, Yip C, et al. Properties of CD34+ CML stem\/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood. 2010;116:2112\u201321.","journal-title":"Blood"},{"key":"3157_CR7","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jnci\/djk150","volume":"99","author":"X Jiang","year":"2007","unstructured":"Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst. 2007;99:680\u201393.","journal-title":"J Natl Cancer Inst"},{"key":"3157_CR8","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell. 2020;37:530\u201342.","journal-title":"Cancer Cell"},{"key":"3157_CR9","doi-asserted-by":"crossref","unstructured":"Alves R, Goncalves AC, Rutella S, Almeida AM, De Las Rivas J, Trougakos IP, et al. Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance. Cancers. 2021;13:4820.","DOI":"10.3390\/cancers13194820"},{"key":"3157_CR10","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190\u20136.","journal-title":"Leukemia"},{"key":"3157_CR11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","volume":"16","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009;16:122\u201331.","journal-title":"Cancer Control"},{"key":"3157_CR12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.stem.2020.04.005","volume":"27","author":"K Rothe","year":"2020","unstructured":"Rothe K, Babaian A, Nakamichi N, Chen M, Chafe SC, Watanabe A, et al. Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors. Cell Stem Cell. 2020;27:110\u201324 e9.","journal-title":"Cell Stem Cell"},{"key":"3157_CR13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121:396\u2013409.","journal-title":"J Clin Invest"},{"key":"3157_CR14","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017;129:1595\u2013606.","journal-title":"Blood"},{"key":"3157_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O\u2019Hare","year":"2012","unstructured":"O\u2019Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer. 2012;12:513\u201326.","journal-title":"Nat Rev Cancer"},{"key":"3157_CR16","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876\u201380.","journal-title":"Science"},{"key":"3157_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06782-9","volume":"20","author":"HJGL Friedman","year":"2020","unstructured":"Friedman HJGL. R. The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib. BMC Cancer. 2020;20:397.","journal-title":"BMC Cancer"},{"key":"3157_CR18","doi-asserted-by":"crossref","unstructured":"Lai D, Chen M, Su J, Liu X, Rothe K, Hu K, et al. PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL(+) human leukemia. Sci Transl Med. 2018;10:eaan8735","DOI":"10.1126\/scitranslmed.aan8735"},{"key":"3157_CR19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jnci\/djt006","volume":"105","author":"M Chen","year":"2013","unstructured":"Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, et al. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. J Natl Cancer Inst. 2013;105:405\u201323.","journal-title":"J Natl Cancer Inst"},{"key":"3157_CR20","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1182\/blood-2003-11-4026","volume":"103","author":"X Jiang","year":"2004","unstructured":"Jiang X, Zhao Y, Chan WY, Vercauteren S, Pang E, Kennedy S, et al. Deregulated expression in Ph+ human leukemias of AHI-1, a gene activated by insertional mutagenesis in mouse models of leukemia. Blood. 2004;103:3897\u2013904.","journal-title":"Blood"},{"key":"3157_CR21","doi-asserted-by":"crossref","first-page":"918","DOI":"10.18632\/oncotarget.405","volume":"2","author":"S Esmailzadeh","year":"2011","unstructured":"Esmailzadeh S, Jiang X. AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders. Oncotarget. 2011;2:918\u201334.","journal-title":"Oncotarget"},{"key":"3157_CR22","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1128\/JVI.76.18.9046-9059.2002","volume":"76","author":"X Jiang","year":"2002","unstructured":"Jiang X, Hanna Z, Kaouass M, Girard L, Jolicoeur P. Ahi-1, a novel gene encoding a modular protein with WD40-repeat and SH3 domains, is targeted by the Ahi-1 and Mis-2 provirus integrations. J Virol. 2002;76:9046\u201359.","journal-title":"J Virol"},{"key":"3157_CR23","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1084\/jem.20072316","volume":"205","author":"LL Zhou","year":"2008","unstructured":"Zhou LL, Zhao Y, Ringrose A, DeGeer D, Kennah E, Lin AE, et al. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem\/progenitor cells. J Exp Med. 2008;205:2657\u201371.","journal-title":"J Exp Med"},{"key":"3157_CR24","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/pmic.201100553","volume":"12","author":"X Liu","year":"2012","unstructured":"Liu X, Chen M, Lobo P, An J, Grace Cheng SW, Moradian A, et al. Molecular and structural characterization of the SH3 domain of AHI-1 in regulation of cellular resistance of BCR-ABL(+) chronic myeloid leukemia cells to tyrosine kinase inhibitors. Proteomics. 2012;12:2094\u2013106.","journal-title":"Proteomics"},{"key":"3157_CR25","doi-asserted-by":"publisher","first-page":"6188","DOI":"10.1038\/sj.onc.1204834","volume":"20","author":"S Xie","year":"2001","unstructured":"Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene. 2001;20:6188\u201395.","journal-title":"Oncogene"},{"key":"3157_CR26","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1038\/leu.2017.108","volume":"31","author":"X Liu","year":"2017","unstructured":"Liu X, Rothe K, Yen R, Fruhstorfer C, Maetzig T, Chen M, et al. A novel AHI-1-BCR-ABL-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy. Leukemia. 2017;31:2376\u201387.","journal-title":"Leukemia"},{"key":"3157_CR27","doi-asserted-by":"crossref","first-page":"24091","DOI":"10.1074\/jbc.R115.675280","volume":"290","author":"WC Merrick","year":"2015","unstructured":"Merrick WC. eIF4F: a retrospective. J Biol Chem. 2015;290:24091\u20139.","journal-title":"J Biol Chem"},{"key":"3157_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nrm2838","volume":"11","author":"RJ Jackson","year":"2010","unstructured":"Jackson RJ, Hellen CU, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol. 2010;11:113\u201327.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3157_CR29","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1101\/gad.13.11.1422","volume":"13","author":"AC Gingras","year":"1999","unstructured":"Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 1999;13:1422\u201337.","journal-title":"Genes Dev"},{"key":"3157_CR30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.molcel.2016.09.020","volume":"64","author":"S Gruner","year":"2016","unstructured":"Gruner S, Peter D, Weber R, Wohlbold L, Chung MY, Weichenrieder O, et al. The Structures of eIF4E-eIF4G Complexes Reveal an Extended Interface to Regulate Translation Initiation. Mol Cell. 2016;64:467\u201379.","journal-title":"Mol Cell"},{"key":"3157_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5790","volume":"5","author":"C Igreja","year":"2014","unstructured":"Igreja C, Peter D, Weiler C, Izaurralde E. 4E-BPs require non-canonical 4E-binding motifs and a lateral surface of eIF4E to repress translation. Nat Commun. 2014;5:4790.","journal-title":"Nat Commun"},{"key":"3157_CR32","doi-asserted-by":"crossref","first-page":"14484","DOI":"10.1074\/jbc.273.23.14484","volume":"273","author":"K Hara","year":"1998","unstructured":"Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem. 1998;273:14484\u201394.","journal-title":"J Biol Chem"},{"key":"3157_CR33","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cels.2021.07.002","volume":"12","author":"S Wu","year":"2021","unstructured":"Wu S, Wagner G. Deep computational analysis details dysregulation of eukaryotic translation initiation complex eIF4F in human cancers. Cell Syst. 2021;12:907\u201323 e6.","journal-title":"Cell Syst"},{"key":"3157_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25798-7","volume":"8","author":"PK Jaiswal","year":"2018","unstructured":"Jaiswal PK, Koul S, Shanmugam PST, Koul HK. Eukaryotic Translation Initiation Factor 4 Gamma 1 (eIF4G1) is upregulated during Prostate cancer progression and modulates cell growth and metastasis. Sci Rep. 2018;8:7459.","journal-title":"Sci Rep"},{"key":"3157_CR35","volume":"120","author":"SH Kim","year":"2023","unstructured":"Kim SH, Choi JH, Marsal-Garcia L, Amiri M, Yanagiya A, Sonenberg N. The mRNA translation initiation factor eIF4G1 controls mitochondrial oxidative phosphorylation, axonal morphogenesis, and memory. Proc Natl Acad Sci USA. 2023;120:e2300008120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3157_CR36","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.tcb.2025.04.006","volume":"35","author":"FE Mercier","year":"2025","unstructured":"Mercier FE, Gife V, Aloyz R, Hulea L. Translational control of leukemic metabolism and disease progression. Trends Cell Biol. 2025;35:971\u201386.","journal-title":"Trends Cell Biol"},{"key":"3157_CR37","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"3157_CR38","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39:1797\u2013813.","journal-title":"Leukemia"},{"key":"3157_CR39","unstructured":"Lambert Y, Pelech S. Applications of high content antibody microarrays for biomarker discovery and trafficking cellular signaling. Adv Proteomics Bioinf. 2018;APBI-107:1\u201324"},{"key":"3157_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58766-1","volume":"10","author":"CR John","year":"2020","unstructured":"John CR, Watson D, Russ D, Goldmann K, Ehrenstein M, Pitzalis C, et al. M3C: Monte Carlo reference-based consensus clustering. Sci Rep. 2020;10:1816.","journal-title":"Sci Rep"},{"key":"3157_CR41","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26:1572\u20133.","journal-title":"Bioinformatics"},{"key":"3157_CR42","first-page":"12","volume":"1","author":"R Kolde","year":"2010","unstructured":"Kolde R. pheatmap. Pretty Heatmaps. 2010;1:12.","journal-title":"Pretty Heatmaps"},{"key":"3157_CR43","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"3157_CR44","doi-asserted-by":"publisher","unstructured":"Blighe K, Rana S, Lewis M. EnhancedVolcano: publication-ready volcano plots with enhanced colouring and labeling. https:\/\/doi.org\/10.18129\/B9.bioc.EnhancedVolcano, R package version 1.26.0. 2025. https:\/\/bioconductor.org\/packages\/EnhancedVolcano.","DOI":"10.18129\/B9.bioc.EnhancedVolcano"},{"key":"3157_CR45","doi-asserted-by":"crossref","first-page":"W191","DOI":"10.1093\/nar\/gkz369","volume":"47","author":"U Raudvere","year":"2019","unstructured":"Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47:W191\u2013W8.","journal-title":"Nucleic Acids Res"},{"key":"3157_CR46","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1182\/blood.2019003636","volume":"136","author":"H Lin","year":"2020","unstructured":"Lin H, Rothe K, Chen M, Wu A, Babaian A, Yen R, et al. The miR-185\/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML. Blood. 2020;136:596\u2013609.","journal-title":"Blood"},{"key":"3157_CR47","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/0008-5472.CAN-14-2789","volume":"75","author":"J Pelletier","year":"2015","unstructured":"Pelletier J, Graff J, Ruggero D, Sonenberg N. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 2015;75:250\u201363.","journal-title":"Cancer Res"},{"key":"3157_CR48","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1038\/sj.emboj.7601166","volume":"25","author":"D Shahbazian","year":"2006","unstructured":"Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, et al. The mTOR\/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J. 2006;25:2781\u201391.","journal-title":"EMBO J"},{"key":"3157_CR49","doi-asserted-by":"crossref","first-page":"715","DOI":"10.18632\/oncotarget.990","volume":"4","author":"JM Gerber","year":"2013","unstructured":"Gerber JM, Gucwa JL, Esopi D, Gurel M, Haffner MC, Vala M, et al. Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget. 2013;4:715\u201328.","journal-title":"Oncotarget"},{"key":"3157_CR50","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/0008-5472.CAN-15-0885","volume":"75","author":"Y Feng","year":"2015","unstructured":"Feng Y, Pinkerton AB, Hulea L, Zhang T, Davies MA, Grotegut S, et al. SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex. Cancer Res. 2015;75:5211\u20138.","journal-title":"Cancer Res"},{"key":"3157_CR51","doi-asserted-by":"crossref","first-page":"43662","DOI":"10.18632\/oncotarget.18216","volume":"8","author":"M Chen","year":"2017","unstructured":"Chen M, Turhan AG, Ding H, Lin Q, Meng K, Jiang X. Targeting BCR-ABL+ stem\/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex. Oncotarget. 2017;8:43662\u201377.","journal-title":"Oncotarget"},{"key":"3157_CR52","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/sj.onc.1209901","volume":"26","author":"S Prabhu","year":"2007","unstructured":"Prabhu S, Saadat D, Zhang M, Halbur L, Fruehauf JP, Ong ST. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogene. 2007;26:1188\u2013200.","journal-title":"Oncogene"},{"key":"3157_CR53","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.3892\/ol.2015.3665","volume":"10","author":"W Zhou","year":"2015","unstructured":"Zhou W, Zhu W, Ma L, Xiao F, Qian W. Proteasome inhibitor MG-132 enhances histone deacetylase inhibitor SAHA-induced cell death of chronic myeloid leukemia cells by an ROS-mediated mechanism and downregulation of the Bcr-Abl fusion protein. Oncol Lett. 2015;10:2899\u2013904.","journal-title":"Oncol Lett"},{"key":"3157_CR54","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1158\/0008-5472.CAN-09-0813","volume":"69","author":"CJ Lin","year":"2009","unstructured":"Lin CJ, Malina A, Pelletier J. c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy. Cancer Res. 2009;69:7491\u20134.","journal-title":"Cancer Res"},{"key":"3157_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44771-9","volume":"15","author":"MT Scott","year":"2024","unstructured":"Scott MT, Liu W, Mitchell R, Clarke CJ, Kinstrie R, Warren F, et al. Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease. Nat Commun. 2024;15:651.","journal-title":"Nat Commun"},{"key":"3157_CR56","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nature18288","volume":"534","author":"SA Abraham","year":"2016","unstructured":"Abraham SA, Hopcroft LE, Carrick E, Drotar ME, Dunn K, Williamson AJ, et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature. 2016;534:341\u20136.","journal-title":"Nature"},{"key":"3157_CR57","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-94-017-9211-0_13","volume":"85","author":"S Bohlman","year":"2014","unstructured":"Bohlman S, Manfredi JJ. p53-independent effects of Mdm2. Subcell Biochem. 2014;85:235\u201346.","journal-title":"Subcell Biochem"},{"key":"3157_CR58","first-page":"1027","volume":"1","author":"G Ganguli","year":"2003","unstructured":"Ganguli G, Wasylyk B. p53-independent functions of MDM2. Mol Cancer Res. 2003;1:1027\u201335.","journal-title":"Mol Cancer Res"},{"key":"3157_CR59","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood-2002-06-1685","volume":"101","author":"M Scherr","year":"2003","unstructured":"Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood. 2003;101:1566\u20139.","journal-title":"Blood"},{"key":"3157_CR60","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2019.08.018","volume":"310","author":"J Valencia-Serna","year":"2019","unstructured":"Valencia-Serna J, Kucharski C, Chen M, Kc R, Jiang X, Brandwein J, et al. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers. J Control Release. 2019;310:141\u201354.","journal-title":"J Control Release"},{"key":"3157_CR61","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jconrel.2024.02.018","volume":"367","author":"AS Ansari","year":"2024","unstructured":"Ansari AS, Remant KC, Morales LC, Nasrullah M, Meenakshi Sundaram DN, Kucharski C, et al. Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models. J Control Release. 2024;367:821\u201336.","journal-title":"J Control Release"},{"key":"3157_CR62","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","volume":"55","author":"AC Lai","year":"2016","unstructured":"Lai AC, Toure M, Hellerschmied D, Salami J, Jaime-Figueroa S, Ko E, et al. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016;55:807\u201310.","journal-title":"Angew Chem Int Ed Engl"},{"key":"3157_CR63","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471\u201384.","journal-title":"Cell"},{"key":"3157_CR64","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s13046-022-02542-8","volume":"41","author":"K Fooks","year":"2022","unstructured":"Fooks K, Galicia-Vazquez G, Gife V, Schcolnik-Cabrera A, Nouhi Z, Poon WWL, et al. EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax. J Exp Clin Cancer Res. 2022;41:340.","journal-title":"J Exp Clin Cancer Res"},{"key":"3157_CR65","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/s41416-020-01205-9","volume":"124","author":"LO Herzog","year":"2021","unstructured":"Herzog LO, Walters B, Buono R, Lee JS, Mallya S, Fung A, et al. Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax. Br J Cancer. 2021;124:1098\u2013109.","journal-title":"Br J Cancer"},{"key":"3157_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-00950-y","volume":"11","author":"TT Vo","year":"2021","unstructured":"Vo TT, Herzog LO, Buono R, Lee JS, Mallya S, Duong MR, et al. Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition. Sci Rep. 2021;11:21689.","journal-title":"Sci Rep"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03157-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03157-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03157-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:56:34Z","timestamp":1792155394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03157-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":66,"alternative-id":["3157"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03157-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.P. is the major shareholder of Kinexus Bioinformatics Corporation. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Authors confirm that all methods described in the study were performed in accordance with relevant institutional guidelines and regulations. We included patient samples with prior fully informed patient consent and approval from the Institutional Ethics Committee at the University of British Columbia - BC Cancer Research Ethics Board (H24-02839). Animal experiments were performed in the Animal Resource Center of the BC Cancer Research Center using procedures approved by the Animal Care Committee of the University of British Columbia (A23-0032). The study was conducted in accordance with the Declaration of Helsinki. No patients directly participated in this study. This study did not include any identifiable images.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}